Crispr Therapeutics Ag (CRSP) — SEC Filings

Overview

Crispr Therapeutics Ag (CRSP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: CRISPR Therapeutics AG reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $450.986 million, up from $328.941 million in the same period of 2024, representing a 37.1% increase. This was primarily driven by a substantial rise in collaboration expense, ne

Sentiment Summary

Across 26 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 21 neutral, 1 mixed. The dominant filing sentiment for Crispr Therapeutics Ag is neutral.

Filing Type Overview

Crispr Therapeutics Ag (CRSP) has filed 6 10-Q, 9 8-K, 1 DEF 14A, 2 10-K, 7 SC 13G/A, 1 DEFA14A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (26)

• CRISPR Therapeutics' Net Loss Widens to $451M Amid R&D Shifts — 10-Q · Nov 10, 2025 Risk: high
  CRISPR Therapeutics AG reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $450.986 million, up from $328.941 mil
• CRISPR Therapeutics Files 8-K — 8-K · Oct 15, 2025 Risk: low
  CRISPR Therapeutics AG filed an 8-K on October 15, 2025, reporting other events and financial statements. The filing does not contain specific details on new ev
• CRISPR Revenue Plunges 90% Amid Vertex Collaboration Shift — 10-Q · Aug 4, 2025 Risk: high
  CRISPR Therapeutics AG reported collaboration revenue of $1.0 million for the three months ended June 30, 2025, a significant decrease from $10.0 million in the
• CRISPR Therapeutics Announces New Gene Therapy Collaboration — 8-K · Jun 26, 2025 Risk: medium
  CRISPR Therapeutics AG announced on June 26, 2025, that it has entered into a collaboration and license agreement with a third party. This agreement involves th
• CRISPR Therapeutics AG Files 8-K — 8-K · Jun 9, 2025 Risk: low
  CRISPR Therapeutics AG filed an 8-K on June 9, 2025, reporting events that occurred on June 5, 2025. The filing indicates amendments to articles of incorporatio
• CRISPR Therapeutics AG Files 8-K Report — 8-K · May 19, 2025 Risk: low
  On May 19, 2025, CRISPR Therapeutics AG filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial state
• CRISPR Therapeutics AG Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  CRISPR Therapeutics AG filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data and business act
• CRISPR Therapeutics AG Executive Compensation Filing — DEF 14A · Apr 16, 2025 Risk: low
  CRISPR Therapeutics AG filed a DEF 14A on April 16, 2025, detailing executive compensation. The filing includes information on equity awards granted in prior ye
• CRISPR Therapeutics AG Files 8-K for Officer/Director Changes — 8-K · Mar 26, 2025 Risk: low
  CRISPR Therapeutics AG announced on March 24, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure
• 10-K Filing — 10-K · Feb 11, 2025
• SC 13G/A Filing — SC 13G/A · Dec 10, 2024
• CRISPR Therapeutics Q3 2024 Update — 10-Q · Nov 5, 2024 Risk: medium
  CRISPR Therapeutics AG filed its Q3 10-Q report for the period ending September 30, 2024. The company reported collaboration revenue for the nine months ended S
• CRISPR Therapeutics AG Files Q2 2024 10-Q — 10-Q · Aug 5, 2024 Risk: medium
  CRISPR Therapeutics AG filed a 10-Q for the period ending June 30, 2024. The company reported on its financial position and business activities, including detai
• CRISPR Therapeutics AG Files 8-K on Corporate Governance and Officer Changes — 8-K · Jun 3, 2024 Risk: low
  CRISPR Therapeutics AG filed an 8-K on May 30, 2024, reporting on several key events. These include the departure of directors or certain officers, the election
• CRISPR Therapeutics Files 8-K on Executive and Board Changes — 8-K · May 23, 2024 Risk: low
  CRISPR Therapeutics AG filed an 8-K on May 23, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain
• CRISPR Therapeutics AG Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
  CRISPR Therapeutics AG (CRSP) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. CRISPR Therapeutics AG filed a 10-Q report for the period ending Marc
• SC 13G/A Filing — SC 13G/A · Apr 10, 2024
• CRISPR Therapeutics Files Proxy Materials — DEFA14A · Apr 9, 2024 Risk: low
  CRISPR Therapeutics AG filed a Definitive Additional Materials (DEFA14A) on April 9, 2024. This filing is related to their proxy statement and indicates no fee
• CRISPR Therapeutics AG Files 2023 Annual Report on Form 10-K — 10-K · Feb 21, 2024 Risk: medium
  CRISPR Therapeutics AG (CRSP) filed a Annual Report (10-K) with the SEC on February 21, 2024. CRISPR Therapeutics AG filed its 2023 Form 10-K on February 21, 20
• CRISPR Therapeutics Files 8-K for Undisclosed "Other Events" — 8-K · Feb 13, 2024 Risk: medium
  CRISPR Therapeutics AG filed an 8-K on February 13, 2024, reporting "Other Events" under Item 8.01. The filing indicates a material event occurred on this date,
• Nikko Asset Management Exits CRISPR Therapeutics Stake — SC 13G/A · Feb 12, 2024 Risk: medium
  Nikko Asset Management Americas, Inc. filed an amended SC 13G/A on February 12, 2024, indicating a significant change in their beneficial ownership of CRISPR Th
• Capital International Investors Trims CRISPR Therapeutics Stake to 7.6% — SC 13G/A · Feb 9, 2024 Risk: low
  Capital International Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing their ownership in CRISPR Therapeutic
• Sumitomo Mitsui Trust Amends CRISPR Therapeutics Stake — SC 13G/A · Feb 5, 2024
  Sumitomo Mitsui Trust Holdings, Inc. (SMTH) filed an amended Schedule 13G/A on February 5, 2024, indicating their beneficial ownership in CRISPR Therapeutics AG
• ARK Investment Management Holds 9.9% Stake in CRISPR Therapeutics — SC 13G/A · Jan 29, 2024
  ARK Investment Management LLC, led by Cathie Wood, filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in CRISPR Therapeutics AG (CRSP) as o
• CRISPR Therapeutics Files 8-K for 'Other Event' on Jan 16, 2024 — 8-K · Jan 16, 2024
  CRISPR Therapeutics AG filed an 8-K on January 16, 2024, to report an "Other Event." This filing primarily serves to update administrative information, confirmi
• ARK Investment Management Discloses 9.9% Stake in CRISPR Therapeutics — SC 13G/A · Jan 10, 2024
  ARK Investment Management LLC, led by Cathie Wood, filed an amended SC 13G/A on January 10, 2024, disclosing its ownership in CRISPR Therapeutics AG as of Decem

Related Companies

VRTX · EDIT · NTLA

Frequently Asked Questions